[Cutaneous manifestations of T-cell prolymphocytic leukemia].
De Belilovsky
C
C
Service de Dermatologie, Institut Gustave-Roussy, Villejuif.
Guillaume
J C
JC
Gilles
E
E
Bosq
J
J
Hayat
M
M
Desvignes
V
V
Avril
M F
MF
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001415:Back; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D005546:Forehead; D006801:Humans; D015463:Leukemia, Prolymphocytic / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012536:Scalp Dermatoses / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D013601:T-Lymphocytes; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Manifestations cutanées au cours d'une leucémie prolymphocytaire à cellules T.